Sarafloxacin
Chemical compound
- QJ01MA98 (WHO)
- 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
- 98105-99-8 N
- 56208
- 50727 Y
- RC3WJ907XY
- ChEMBL37858 Y
- DTXSID8048494
- Interactive image
- Fc1ccc(cc1)N\3c2cc(c(F)cc2C(=O)C(/C(=O)O)=C/3)N4CCNCC4
InChI
- InChI=1S/C20H17F2N3O3/c21-12-1-3-13(4-2-12)25-11-15(20(27)28)19(26)14-9-16(22)18(10-17(14)25)24-7-5-23-6-8-24/h1-4,9-11,23H,5-8H2,(H,27,28) Y
- Key:XBHBWNFJWIASRO-UHFFFAOYSA-N Y
Sarafloxacin (INN) is a quinolone antibiotic drug,[1][2] which was removed from clinical use by its manufacturer Abbott Laboratories from April 30, 2001.
See also
- Quinolone
- Adverse effects of fluoroquinolones
References
- ^ "Evaluation of certain veterinary drug residues in food. Fiftieth report of the joint FAO/WHO Expert Committee on Food Additives". World Health Organization Technical Report Series. 888: i–vii, 1–95. 1999. PMID 10416362.
- ^ Gingerich WH, Stehly GR, Clark KJ, Hayton WL (1998). "Crop grouping: a proposal for public aquaculture". Veterinary and Human Toxicology. 40 (Suppl 2): 24–31. PMID 9823579.
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor | |||||||||
---|---|---|---|---|---|---|---|---|---|
Sulfonamides (DHPS inhibitor) |
| ||||||||
Combinations |
| ||||||||
Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation | |||||||||
---|---|---|---|---|---|---|---|---|---|
Fluoroquinolones |
| ||||||||
Newer non-fluorinated | |||||||||
Related (DG) |
inhibitors
Nitroimidazole derivatives | |
---|---|
Nitrofuran derivatives |
Rifamycins/ RNA polymerase | |
---|---|
Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e